Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Dr. Reddy's Laboratories - Outperformance continues - ICICI Securities

Posted On: 2020-10-29 05:44:32


Dr. Reddy's Laboratories' (DRL) has reported strong Q2FY21 performance above our estimates on all fronts. Revenue grew 20.1% YoY to Rs49.0bn (I-Sec: Rs48.0bn) driven by growth across segments. EBITDA margin at 24.9% was higher than estimated 23.7%. Adjusted PAT grew 98.5% to Rs8.3bn (I-Sec: Rs6.3bn). US grew 7.9% QoQ to $247mn led by new launches and traction in the base business. India revenue grew 21.5% YoY aided by acquisition of Wockhardt's domestic branded generics portfolio (Jun'20). We expect the growth momentum in branded generics business (India & EMs) and new launches in US to continue in coming quarters supporting growth. Hence we maintain ADD with a revised target price of Rs5,485/share.

- Growth across segments: India sales grew 20.1% YoY and 45.7% QoQ with consolidation of Wockhardt products which was completed in Jun'20. US revenue grew 7.9% QoQ to US$247mn vs estimated US$240mn led by nine new launches and traction in the base business. PSAI business segmented reported strong growth of 19.7% YoY, however, lower volumes of certain products caused a muted performance sequentially. EU generics also reported strong 35.8% growth led by new launches and high traction in volumes across markets. EM revenues grew 6.5% led by CIS and ROW with new launches and strong traction in volumes. Russia grew 21.2% as it recovers from the lows of Q1FY21 which was impacted by COVID-19.

- Margins high but decline sequentially: Gross margin stood at 53.9%, up 250 YoY but declined 200bps QoQ. Sequential decline was on account of lower export incentive and unfavourable business mix & forex movement. Subsequently EBITDA margin grew 410bps YoY but declined 30bps QoQ to 24.9%. Gross margin in global generics rose 390bps YoY to 59.4% and that in PSAI improved 220bps to 26.8%. However, these margins declined 200bps YoY and 660bps QoQ for generics and PSAI respectively. Gross margin has been quite volatile on quarterly basis and we expect it to remain ~54-56% vs 52.2% in FY20.

- Outlook: Overall, we expect revenues and earnings to grow at 14.0% and 35.5% CAGRs, respectively, over FY20-FY23E with 840bps EBITDA margin expansion. Margin expansion would be largely driven by improving revenue mix leading to higher gross margin and controlled S,G&A expenses. We expect the company to generate free cash flow of Rs 73bn over the next three years.

- Valuations and risks: We largely maintain our revenue estimates but increase EPS estimates by 4-6% for FY21E-FY23E to factor-in better margin profile and lower tax rate. We maintain ADD on the stock with a revised target price of Rs5,485/share based on 25xSep'22E EPS and an additional Rs514/share for Revlimid (earlier: Rs5,214/share). Key downside risks: delay in launching new products, regulatory hurdles and currency volatility.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.4942.45 as compared to the previous close of Rs. 4949.8. The total number of shares traded during the day was 47875 in over 5865 trades.

The stock hit an intraday high of Rs. 5041.6 and intraday low of 4892.8. The net turnover during the day was Rs. 238162680.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Auto Sector - Monthly Volume Round-up - Nov 20 - Reliance Securities

What do brokerages say on Burger King India Limited's IPO?

The Phoenix Mills - Potential fund infusion may usher in growth - ICICI Securities

Godrej Agrovet - Beneficiary of 60% increase in palm oil prices - ICICI Securities

Automobiles (wholesale) - Wholesale dispatches rise amidst modest retail trends - ICICI Securities

Oil & Gas - Sector Update - Dec 2020 - ICICI Direct

Phoenix Mills (Buy): Asset monetisation at favourable terms... - ICICI Direct

Aditya Makharia's views on November Auto Sales Number for November 2020 - HDFC Securities

Burger King India - IPO Review - ICICI Direct

Quant Pick - LIC Housing Finance - ICICI Direct

Tech Mahindra - Analyst Meet Update - ICICI Direct

Gladiator Stocks - Crompton Greaves Consumer Electricals - ICICI Direct

Derivatives Monthly Outlook - Nifty support at 12800 for ongoing momentum...

Quant Pick - Sun Pharmaceuticals - ICICI Direct

Monetary Policy - Expectation from YES Securities

Sector Update on Asset Management Companies - Subdued but improvement expected - HDFC Securities

Pre Monetary Policy View - Dec, 2020 - Lakshmi Iyer, President and CIO (Debt) & Head Products, Kotak Mutual Fund

Maintain REDUCE on Siemens - Smart recovery priced in - HDFC Securities

Banking Sector Credit Trends - Growth continues to moderate - HDFC Securities

Q2 FY21 GDP: Light at the end of the tunnel - YES Securities

Siemens - Q4 FY20 Result Update - YES Securities

Super action in Home Loans - SBIN, ICICIBC, AXSB, HDFC and LICHF gaining share - YES Securities

Polymer price tracker - Dec 1, 2020 - PVC prices continue to tread higher - ICICI Securities

Bajaj Finance - Company Update - Dec 2020 - ICICI Direct

Siemens Ltd - Healthy revival in orders and margins - ICICI Securities

Covid Recovery Pulse - Nov 30, 2020 - Festive positivity continues in auto retails, e-way bill generation improves...

Derivatives Weekly View (November 27): Momentum expected to continue in broader markets with Nifty support at 12800...

Derivatives Strategy - Positional Option - ICICI Direct

Preview on RBI Monetary Policy - December 2020 - Shanti Ekambaram, Group President - Consumer Banking, Kotak Mahindra Bank

10 things you should know about Burger King India Limited

Views of HDFC Securities and Acuité Ratings & Research on Q2FY21 GDP Numbers

Rollover Report for November 2020 - December 2020: Angel Broking

Initiating Coverage on Godrej Properties - The housing factory - HDFC Securities

Burger King IPO - Angel Broking

Rollover Analysis - Record foreign inflows pushes Nifty to 13k - YES Securities

Ceramic tiles industry - Market share gains sustain for top branded players - ICICI Securities

Gas sector - CGD: Competition to hit margins, volumes and lead to derating - ICICI Securities

Cement - Prices resilient in Q3; consensus upgrades to continue - ICICI Securities

Specialty chemicals - Price trend in Sep-20 - ICICI Securities

Timken India - Q2FY21 Company Update - ICICI Direct

Upgrade in target price of IDFC First Bank - Angel Broking

Laurus Labs stake acquisition in Richore Lifesciences - Angel Broking

Shares of Lakshmi Vilas Bank (LVB) suspended from trading - Angel Broking

Initiating Coverage on Sundram Fasteners - Fastening growth - HDFC Securities

Astral Poly Technik - Scalability to further improve with storage tanks foray - ICICI Securities

Vardhman Special Steel - Q2FY21 Company Update - ICICI Direct

Initiating Coverage - Advanced Enzyme Technologies - ICICI Direct

L&T - Secures Large Contract - Nov 25, 2020 - Angel Broking

Alembic Pharmaceuticals - Tentative Approval for JV - Angel Broking

Drug launch by Lupin - Tacrolimus Capsules - Angel Broking



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019